Kancera Q2 2024: Initial comment - Redeye

Redeye provides an initial comment on the Q2 2024 report from Kancera, which showed lower operating costs than we had foreseen. The lower cost base is driven by a reduction of R&D spend, explained by the FRACTAL study being ongoing in the comparable period. The company also published an operational update in conjunction with the quarterly report. All in all, the report contained no surprises, and we are encouraged by the continued clinical progress.

Länk till analysen i sin helhet: https://www.redeye.se/research/1034130/kancera-q2-2024-initial-comment?utm_source=finwire&utm_medium=RSS